Expertise in
19
conditions

Daniel A. Gaudet

Chicoutimi, QC, CA 
Expertise in
19
conditions
Chicoutimi, QC, CA 

Overview

Daniel Gaudet practices practicing medicine in Chicoutimi, Canada.

Mr. Gaudet is highly rated in 19 conditions, according to our data. His clinical expertise encompasses High Cholesterol, Familial Hypertriglyceridemia, Familial Lipoprotein Lipase Deficiency, and Apolipoprotein C2 Deficiency.

He is actively involved in clinical research, co-authoring 238 peer reviewed articles and participating in 7 clinical trials.

Gender

Male

Locations

Chicoutimi, QC, Canada
Other Locations
Chicoutimi, Canada
Kelowna, BC, Canada
Montreal, QC, Canada
Saguenay, QC, Canada
Quebec, QC, Canada
Lethbridge, AB T1K3M4, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Phase 2 Study to Evaluate the Safety and Efficacy of ARO-ANG3 in Subjects With Homozygous Familial Hypercholesterolemia (HOFH)
Phase 2 Study to Evaluate the Safety and Efficacy of ARO-ANG3 in Subjects With Homozygous Familial Hypercholesterolemia (HOFH)
Enrollment Status: Terminated
Publish Date: June 12, 2026
Intervention Type: Drug
Study Drug: ARO-ANG 3
Study Phase: Phase 2
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia
Enrollment Status: Completed
Publish Date: March 24, 2026
Intervention Type: Drug
Study Drug: ARO-APOC3
Study Phase: Phase 2
A Phase 1 Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-APOC3 in Adult Healthy Volunteers as Well as in Severely Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome
A Phase 1 Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-APOC3 in Adult Healthy Volunteers as Well as in Severely Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome
Enrollment Status: Completed
Publish Date: December 24, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-ANG3 in Adults With Mixed Dyslipidemia
A Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-ANG3 in Adults With Mixed Dyslipidemia
Enrollment Status: Completed
Publish Date: December 03, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3561774 in Adults With Mixed Dyslipidemia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3561774 in Adults With Mixed Dyslipidemia
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug
Study Drug: LY3561774
Study Phase: Phase 2
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Enrollment Status: Completed
Publish Date: June 25, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double Blind, Placebo-Controlled, Dose Titration, Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 494372 Administered Subcutaneously to Patients With High Lipoprotein(a)
A Randomized, Double Blind, Placebo-Controlled, Dose Titration, Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 494372 Administered Subcutaneously to Patients With High Lipoprotein(a)
Enrollment Status: Completed
Publish Date: December 20, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

238 Total Publications

New and Emerging Therapeutic Targets for ApoB-Containing Particles Lowering.
New and Emerging Therapeutic Targets for ApoB-Containing Particles Lowering.
Journal: Circulation research
Published: June 04, 2026

Frequently Asked Questions about Daniel A. Gaudet

Is Daniel A. Gaudet a top-rated expert for High Cholesterol?

MediFind is an objective health platform that identifies experts based on real-world data. Daniel A. Gaudet is classified as an Elite expert for High Cholesterol, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Daniel A. Gaudet participate in research or clinical trials?

Yes. Daniel A. Gaudet has published 238 articles and abstracts on conditions like High Cholesterol. You can view a list of Daniel A. Gaudet's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Gaudet's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 19 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile